

Consensus Meeting on Methodological Considerations for Suicide Assessment and Clinical Trial Design

Pre-meeting Working Group Members

Nomenclature and Classification

Gregory	Brown*	University of Pennsylvania
Lisa	Brenner*	Denver VA Medical Center
Phillip	Chappell, Chair Support	Pfizer, Inc.
Diego	de Leo	Griffith University
Suresh	Durgam	Allergan
Robert	Goldman	Sunovion
Shane	McInerney	UHN Toronto
Kelly	Posner*	Columbia University/New York State Psychiatric Institute
John	Rush	Duke-nus
David	Sheehan	University of South Florida College of Medicine
Morton	Silverman, Chair	Suicide Prevention Resource Center - EDC
Leonardo	Tondo	Harvard Medical School, McLean Hospital

Instrumentation and Special Populations

Mark	Bangs	Eli Lilly and Co.
Florence	Butlen	European Medicines Agency
Martin	Cheatle	University of Pennsylvania
Wen-Hung	Chen	FDA
Christine	Gispén-de Wied	Medicines Evaluation Board
John	Greist	Healthcare Technology Systems
Manuel	Haas	European Medicines Agency

Jill	Harkavy-Friedman, Chair Support	American Foundation for Suicide Prevention
Lynne	Johnson	Eli Lilly and Co.
John	Mann	Columbia University
Derrick	McKinley	Pfizer, Inc.
Donna	Palumbo	Pfizer, Inc.
Joseph	Palumbo	Mitsubishi Tanabe Pharma Development America, Inc.
Michael	Ryan	Novartis
Paramala	Santosh	Institute of Psychiatry; King's College, London
Barbara	Stanley*	Columbia University
Steven	Targum, Chair	Clintara, LLC
Oleg	Tcheremissine	Carolinas HealthCare System
Lynn	Webster	PRA Health Sciences
Janet	Williams	MedAvante
Christian	Yavorsky	CROnos CCS, Inc.

Analysis of SIB Data

Munaf	Ali	Munaf Ali Consultancy, Ltd.
John	Davies	GlaxoSmithKline
Bryan	Dirks	Shire
Sarah	DuBrava, Chair Support	Pfizer, Inc.
Rebecca	Evans	Parexel
Michael	Federico	ERT
Andrew	Freeman	University of Nevada, Las Vegas
Mark	Gordon	Boehringer Ingelheim
Pilar	Lim, Chair	Janssen Research and Development, LLC
Cristiana	Mayer	Janssen Research and Development, LLC

Mary	Nilsson	Eli Lilly and Co.
Jill	Rasmussen	psi-napse
Weining	Robieson	AbbVie
Madhukar	Trivedi	University Of Texas Southwestern Medical School
Christine	Ulbricht	University of Massachusetts Medical School
Anna	Van Meter	Albert Einstein College of Medicine
Benedetto	Vitiello	NIMH
Jun	Zhao	AbbVie

Design and Methodology for SIB Treatment Studies

Heather	Bryson	PPD
Bob	Buchanan	Maryland Psychiatric Research Center
Carla	Canuso	Janssen Research and Development
Jordan	DeVylder	University of Maryland, Baltimore
Franco	Di Cesare, Chair	Leoben Research, Ltd.
Ebrahim	Haroon	Emory University
Yuko	Hirata	INC Research
Sid	Kennedy	University of Toronto; University Health Network
Andrew	Krystal	Duke University
William	Lenderking	Evidera
Jean-Pierre	Lindenmayer	New York University
Herb	Meltzer	Northwestern University
Charlie	Nemeroff	University of Miami
Andy	Nierenberg	Massachusetts General Hospital
Tina	Oakes	Eli Lilly and Company
Eliseo	Salinas	Turing Pharmaceuticals

David	Sheehan	University of South Florida College of Medicine
Michelle	Stewart, Chair Support	Pfizer, Inc.
David	Walling	Collaborative NeuroScience Network, Inc.

Developing Policy and Education on SIB Assessment

Larry	Adler	University of Maryland School of Medicine
Larry	Alphs, Chair Support	Janssen Scientific Affairs, LLC
Reyn	Archer	Vieo Health Strategies
Sharon	Fernando	INC Research
John	Greden	Rachel Upjohn
Joe	Hulihan	Paradigm Consulting, LLC
Edward	Kim	Janssen Pharmaceutica
Christopher	Kosseff	Rutgers University Behavioral Health Care
Mark	Lerman	Chicago Lakeshore Hospital
John	Madigan	American Foundation for Suicide Prevention/SPAN USA
Heddie	Martynowicz	Janssen Research and Development, LLC
Maju	Mathews	Janssen Pharmaceuticals
Sian	Ratcliffe, Chair	Pfizer Worldwide Research and Development
Nicolas	Werner	Richmond Fellowship
Sid	Zisook	University of California, San Diego

** Requests not to be listed as contributor to the manuscript.*